{"id":10389,"date":"2026-10-14T06:40:30","date_gmt":"2026-10-14T11:40:30","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=10389"},"modified":"2026-10-14T09:06:45","modified_gmt":"2026-10-14T14:06:45","slug":"nanoscope-therapeutics-appoints-gene-therapy-operations-leader-troy-short-as-senior-vice-president-manufacturing-and-supply-chain","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/ja\/2026\/10\/14\/nanoscope-therapeutics-appoints-gene-therapy-operations-leader-troy-short-as-senior-vice-president-manufacturing-and-supply-chain\/","title":{"rendered":"Nanoscope Therapeutics Appoints Gene Therapy Operations Leader Troy Short as Senior Vice President, Manufacturing and Supply Chain"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"10389\" class=\"elementor elementor-10389\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-6d5ad04f elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"6d5ad04f\" data-element_type=\"section\" data-e-type=\"section\">\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-5bf9bdef\" data-id=\"5bf9bdef\" data-element_type=\"column\" data-e-type=\"column\">\r\n\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-e3a8c93 elementor-widget-tablet__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"e3a8c93\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li><em>Operations and supply chain executive with more than 20 years of experience spanning\u00a0GMP manufacturing, global clinical and commercial supply, and gene therapy launch execution<\/em><\/li><li><em>Former VP of Global Supply Chain and interim Chief Technical Officer at\u00a0AveXis, where he built and led the global supply chain organization through the launch of Zolgensma\u00ae across more than 30 countries<\/em><\/li><li><em>Appointment strengthens manufacturing and supply chain leadership as Nanoscope advances lead product MOGENRY\u00ae through regulatory review toward potential global commercialization<\/em><\/li><\/ul><p><span class=\"legendSpanClass\">\u30c0\u30e9\u30b9<\/span>, <span class=\"legendSpanClass\">Oct. 14, 2026<\/span>\u00a0 \u2014 <a href=\"http:\/\/nanostherapeutics.com\/ja\/\" target=\"_blank\" rel=\"nofollow noopener\">\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9<\/a>\u00a0Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced the appointment of Troy Short as Senior Vice President, Manufacturing and Supply Chain. In this role, Short will lead Nanoscope&#8217;s GMP manufacturing, commercial supply, and global distribution strategy as the company advances toward the potential approval and launch of <b>MOGENRY\u00ae<\/b><b> (sonpiretigene isteparvovec; MCO-010)<\/b>.<\/p><p>Mr. Short brings more than two decades of operations and supply chain leadership across the pharmaceutical and gene therapy industries, with particular depth in building the manufacturing and distribution capabilities required to bring genetic medicines to patients. He previously served as Vice President of Global Supply Chain at AveXis, Inc., where he built and led the global commercial supply chain organization through the launch of Zolgensma\u00ae, scaling distribution globally, including the design of the specialized cold-chain model required for patient-specific delivery. He negotiated supply agreements, managed raw material sourcing, led the enterprise resource planning system implementation, and played a leadership role in FDA licensure and commercial readiness. Following the acquisition of AveXis by Novartis, he served as interim Chief Technical Officer during the transition.<\/p><p>Mr. Short subsequently served as Senior Vice President of Manufacturing and Supply Chain at Jaguar Gene Therapy, where he built Jaguar&#8217;s CMC and supply chain organization, internalized process and analytical development, and directed the design of their GMP manufacturing facility. He later served as Chief Operating Officer of Advanced Medicine Partners, leading the design and startup of their GMP facility. Most recently, through his firm GTxConsulting, he has advised biotechnology companies and investment firms on CMC strategy, as well as supply chain and BLA readiness for gene therapies and other advanced modalities. Earlier in his career, Mr. Short spent 11 years at Hospira, a Pfizer company, as Director of Supply Chain for sterile pharmaceutical manufacturing.<\/p><p>&#8220;Troy has done what very few people in our industry have done: built and run the supply chain that delivered an approved AAV gene therapy to patients around the world,&#8221; said Sulagna Bhattacharya, Co-Founder and Chief Executive Officer of Nanoscope Therapeutics. &#8220;A one-time intravitreal therapy manufactured in the U.S. has to reach every patient who needs it, at quality, without interruption. That capability is built years in advance, and Troy knows exactly how to execute. His arrival at this stage reflects how seriously we are taking our preparation for launch.&#8221;<\/p><p>Nanoscope continues to build clinical, regulatory, scaled-up manufacturing, and commercial-preparation momentum in support of MOGENRY for inherited retinal dystrophies (IRDs). The U.S. Food and Drug Administration (FDA) has\u00a0<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4797592-1&amp;h=2241603619&amp;u=https%3A%2F%2Fnanostherapeutics.com%2F2026%2F09%2F09%2Fnanoscope-therapeutics-announces-u-s-food-and-drug-administration-acceptance-of-biologics-license-application-for-mogenry-for-the-treatment-of-retinitis-pigmentosa-with-severe-vision-loss%2F&amp;a=accepted+and+filed+the+company%27s+Biologics+License+Application+(BLA)+for+MOGENRY+for+the+treatment+of+retinitis+pigmentosa+(RP)\" target=\"_blank\" rel=\"nofollow noopener\">accepted and filed the company&#8217;s Biologics License Application (BLA) for MOGENRY for the treatment of retinitis pigmentosa (RP)<\/a> with severe vision loss. The BLA is presently under FDA review.\u00a0A <a href=\"https:\/\/nanostherapeutics.com\/ja\/2026\/10\/01\/nanoscope-therapeutics-announces-pmda-acceptance-and-priority-review-of-new-drug-application-for-mogenry-in-japan-for-the-treatment-of-inherited-retinal-dystrophies\/\" target=\"_blank\" rel=\"nofollow noopener\">Japan New Drug Application (JNDA)<\/a>\u00a0for MOGENRY is also currently under PMDA\u00a0review for IRDs.\u00a0These milestones reflect the company&#8217;s expanding international regulatory pathway as it advances commercialization planning across key global markets.<\/p><p>&#8220;MOGENRY is designed to work regardless of the gene behind a patient&#8217;s vision loss. My job is to make sure it reaches them,&#8221; said Short. &#8220;My focus will be on strengthening our manufacturing partnerships, building a resilient commercial supply chain, and making sure patients and their physicians can count on product availability upon its potential approval.&#8221;\u00a0<\/p><p><b>About Inherited Retinal Dystrophies<\/b><br class=\"dnr\" \/>Inherited retinal dystrophies (IRDs) are a genetically diverse group of rare disorders, caused by mutations in more than 250 genes, in which progressive loss of photoreceptor cells leads to impaired vision and, in most cases, complete blindness. IRDs include retinitis pigmentosa, the most common IRD, as well as Stargardt disease, cone-rod dystrophies, and Leber congenital amaurosis, among others. Because gene-specific therapies address only a single genetic cause, the vast majority of patients with IRDs have no approved treatment option.<\/p><p><b>About MOGENRY (sonpiretigene isteparvovec; MCO-010)<\/b><br class=\"dnr\" \/>Nanoscope&#8217;s multi-characteristic opsin (MCO) technology utilizes a proprietary genetically engineered synthetic opsin to enable optimized performance in terms of high light sensitivity across a broad spectrum and fast kinetics. After Nanoscope&#8217;s Co-Founder, President, and Chief Scientific Officer, Samarendra Mohanty, envisioned and invented the technology, his team spent more than a decade evaluating its performance across multiple animal models and human diseases. MOGENRY is an investigational, one-time, in-office, intravitreal optogenetic gene therapy built on Nanoscope&#8217;s MCO platform. By delivering a multi-characteristic opsin gene to the highly dense bipolar retinal cells, MOGENRY makes these surviving cells directly light-sensitive, enabling them to utilize the remaining visual circuitry following photoreceptor loss. MOGENRY does not require genetic testing, invasive surgery, or repeat dosing, and is designed for administration within existing retina office workflows.<\/p><p><b>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u306b\u3064\u3044\u3066<br class=\"dnr\" \/><\/b>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u306f\u3001\u7db2\u819c\u5909\u6027\u75be\u60a3\u306b\u3088\u308a\u5931\u660e\u3057\u305f\u6570\u767e\u4e07\u4eba\u306e\u60a3\u8005\u306e\u305f\u3081\u306b\u3001\u75be\u60a3\u306e\u7a2e\u985e\u3092\u554f\u308f\u305a\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u5149\u907a\u4f1d\u5b66\u7684\u6cbb\u7642\u6cd5\u3092\u958b\u767a\u3057\u3066\u3044\u307e\u3059\u3002\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\u3092\u5bfe\u8c61\u3068\u3057\u305f\u591a\u65bd\u8a2d\u5171\u540c\u7121\u4f5c\u70ba\u5316\u4e8c\u91cd\u76f2\u691c\u30d7\u30e9\u30bb\u30dc\u5bfe\u7167\u81e8\u5e8a\u8a66\u9a13\u3067\u3042\u308bRESTORE\u7b2c2b\/3\u76f8\u8a66\u9a13\u3067\u826f\u597d\u306a\u7d50\u679c\u304c\u5f97\u3089\u308c\u305f\u3053\u3068\u3092\u53d7\u3051\u3001<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04945772\" target=\"_blank\" rel=\"nofollow noopener\">NCT04945772<\/a>), the FDA has accepted and filed the company&#8217;s BLA for MOGENRY, and the PMDA has accepted for priority review the company&#8217;s Japan new drug application (JNDA) for MOGENRY for the treatment of IRDs. If approved, MOGENRY has the potential to become the standard of care for patients with RP and other IRDs, administered as a one-time, in-office injection without the need for genetic testing. The company has also shown promising results in the STARLIGHT Phase 2 clinical trial (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05417126\" target=\"_blank\" rel=\"nofollow noopener\">NCT05417126<\/a>) of MCO-010 in Stargardt disease (SD) and plans to initiate a Phase 3 registrational trial in 2026. MCO-010 has received FDA Fast Track and Orphan Drug designations for both RP and SD, along with Regenerative Medicine Advanced Therapy (RMAT) designation for SD, and European Medicines Agency (EMA) Orphan designations covering non-syndromic and syndromic rod- and cone-dominant dystrophies, as well as macular dystrophies. MCO-010 has also received Sakigake and Orphan designations for IRDs in Japan and an Orphan designation for IRDs in Saudi Arabia. A Phase 2 program for MCO in geographic atrophy is expected to\u00a0start in 2026, and other investigational new drug (IND)-ready programs include Leber congenital amaurosis (LCA). Learn more at\u00a0<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4797592-1&amp;h=1433088080&amp;u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___http%3A%2F%2Fnanostherapeutics.com%2F___.YXAzOm5hbm9zY29wZXRoZXJhcGV1dGljczpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDpmMjhlNDcwZGQzYTY0MWQzZDVjYTc4ODBiYTU1YzE0OTo3OjRhOGM6ODg5YmU2YTQwZTlhNTk0ZDA0ZDRiYjZjNGE2Mzk0YmVhZDhiNGUwMTE3ODI1NGFkOTJlMTg0YmFkYmUyNDAwNzpwOlQ6Rg&amp;a=NanosTherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\"><b>NanosTherapeutics.com<\/b><\/a>\u00a0and follow @NSTherapeutics on X and on LinkedIn.\u00a0<\/p><p><b>\u63a5\u89e6\uff1a<br class=\"dnr\" \/><\/b>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u682a\u5f0f\u4f1a\u793e<br class=\"dnr\" \/>+1 (817) 857-1186<br class=\"dnr\" \/><a href=\"mailto:PR@nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">PR@nanostherapeutics.com<\/a><\/p><p>SOURCE Nanoscope Therapeutics\u00ae<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Operations and supply chain executive with more than 20 years of experience spanning\u00a0GMP manufacturing, global clinical and commercial supply, and gene therapy launch execution Former VP of Global Supply Chain and interim Chief Technical Officer at\u00a0AveXis, where he built and led the global supply chain organization through the launch of Zolgensma\u00ae across more than 30 countries Appointment strengthens manufacturing and supply chain leadership as Nanoscope advances lead product MOGENRY\u00ae through regulatory review toward potential global commercialization DALLAS, Oct. 14, 2026\u00a0 &#8212; Nanoscope Therapeutics\u00a0Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced the appointment [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":10390,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-10389","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics Appoints Gene Therapy Operations Leader Troy Short as Senior Vice President, Manufacturing and Supply Chain - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/ja\/2026\/10\/14\/nanoscope-therapeutics-appoints-gene-therapy-operations-leader-troy-short-as-senior-vice-president-manufacturing-and-supply-chain\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Appoints Gene Therapy Operations Leader Troy Short as Senior Vice President, Manufacturing and Supply Chain - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/ja\/2026\/10\/14\/nanoscope-therapeutics-appoints-gene-therapy-operations-leader-troy-short-as-senior-vice-president-manufacturing-and-supply-chain\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-14T11:40:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-14T14:06:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Wilson PJ\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"Wilson PJ\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"5\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/10\\\/14\\\/nanoscope-therapeutics-appoints-gene-therapy-operations-leader-troy-short-as-senior-vice-president-manufacturing-and-supply-chain\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/10\\\/14\\\/nanoscope-therapeutics-appoints-gene-therapy-operations-leader-troy-short-as-senior-vice-president-manufacturing-and-supply-chain\\\/\"},\"author\":{\"name\":\"Wilson PJ\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\"},\"headline\":\"Nanoscope Therapeutics Appoints Gene Therapy Operations Leader Troy Short as Senior Vice President, Manufacturing and Supply Chain\",\"datePublished\":\"2026-10-14T11:40:30+00:00\",\"dateModified\":\"2026-10-14T14:06:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/10\\\/14\\\/nanoscope-therapeutics-appoints-gene-therapy-operations-leader-troy-short-as-senior-vice-president-manufacturing-and-supply-chain\\\/\"},\"wordCount\":1115,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/10\\\/14\\\/nanoscope-therapeutics-appoints-gene-therapy-operations-leader-troy-short-as-senior-vice-president-manufacturing-and-supply-chain\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_TroyShortPR_REV2.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"ja\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/10\\\/14\\\/nanoscope-therapeutics-appoints-gene-therapy-operations-leader-troy-short-as-senior-vice-president-manufacturing-and-supply-chain\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/10\\\/14\\\/nanoscope-therapeutics-appoints-gene-therapy-operations-leader-troy-short-as-senior-vice-president-manufacturing-and-supply-chain\\\/\",\"name\":\"Nanoscope Therapeutics Appoints Gene Therapy Operations Leader Troy Short as Senior Vice President, Manufacturing and Supply Chain - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/10\\\/14\\\/nanoscope-therapeutics-appoints-gene-therapy-operations-leader-troy-short-as-senior-vice-president-manufacturing-and-supply-chain\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/10\\\/14\\\/nanoscope-therapeutics-appoints-gene-therapy-operations-leader-troy-short-as-senior-vice-president-manufacturing-and-supply-chain\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_TroyShortPR_REV2.jpg\",\"datePublished\":\"2026-10-14T11:40:30+00:00\",\"dateModified\":\"2026-10-14T14:06:45+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/10\\\/14\\\/nanoscope-therapeutics-appoints-gene-therapy-operations-leader-troy-short-as-senior-vice-president-manufacturing-and-supply-chain\\\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/10\\\/14\\\/nanoscope-therapeutics-appoints-gene-therapy-operations-leader-troy-short-as-senior-vice-president-manufacturing-and-supply-chain\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/10\\\/14\\\/nanoscope-therapeutics-appoints-gene-therapy-operations-leader-troy-short-as-senior-vice-president-manufacturing-and-supply-chain\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_TroyShortPR_REV2.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_TroyShortPR_REV2.jpg\",\"width\":1200,\"height\":1200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/10\\\/14\\\/nanoscope-therapeutics-appoints-gene-therapy-operations-leader-troy-short-as-senior-vice-president-manufacturing-and-supply-chain\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Appoints Gene Therapy Operations Leader Troy Short as Senior Vice President, Manufacturing and Supply Chain\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\",\"name\":\"Wilson PJ\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics Appoints Gene Therapy Operations Leader Troy Short as Senior Vice President, Manufacturing and Supply Chain - Nanoscope Therapeutics","description":"\u5f53\u793e\u306e\u591a\u6a5f\u80fd\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u4f34\u3046\u7db2\u819c\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u80fd\u529b\u3092\u5b9f\u8a3c\u3057\u305f\u521d\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002Nanoscope\u793e\u306f\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u3001\u5e83\u7bc4\u56f2\u306e\u30b9\u30da\u30af\u30c8\u30eb\u3001\u9ad8\u901f\u5fdc\u7b54\u6027\u3001\u8d85\u9ad8\u611f\u5ea6\u3092\u5099\u3048\u305f\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u6700\u521d\u3067\u552f\u4e00\u306e\u5149\u907a\u4f1d\u5b66\u6280\u8853\u3067\u3042\u308bMCO-010\u3092\u958b\u767a\u3057\u307e\u3057\u305f\u3002.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/ja\/2026\/10\/14\/nanoscope-therapeutics-appoints-gene-therapy-operations-leader-troy-short-as-senior-vice-president-manufacturing-and-supply-chain\/","og_locale":"ja_JP","og_type":"article","og_title":"Nanoscope Therapeutics Appoints Gene Therapy Operations Leader Troy Short as Senior Vice President, Manufacturing and Supply Chain - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/ja\/2026\/10\/14\/nanoscope-therapeutics-appoints-gene-therapy-operations-leader-troy-short-as-senior-vice-president-manufacturing-and-supply-chain\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2026-10-14T11:40:30+00:00","article_modified_time":"2026-10-14T14:06:45+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Wilson PJ","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"\u57f7\u7b46\u8005":"Wilson PJ","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"5\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2026\/10\/14\/nanoscope-therapeutics-appoints-gene-therapy-operations-leader-troy-short-as-senior-vice-president-manufacturing-and-supply-chain\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2026\/10\/14\/nanoscope-therapeutics-appoints-gene-therapy-operations-leader-troy-short-as-senior-vice-president-manufacturing-and-supply-chain\/"},"author":{"name":"Wilson PJ","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d"},"headline":"Nanoscope Therapeutics Appoints Gene Therapy Operations Leader Troy Short as Senior Vice President, Manufacturing and Supply Chain","datePublished":"2026-10-14T11:40:30+00:00","dateModified":"2026-10-14T14:06:45+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/10\/14\/nanoscope-therapeutics-appoints-gene-therapy-operations-leader-troy-short-as-senior-vice-president-manufacturing-and-supply-chain\/"},"wordCount":1115,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/10\/14\/nanoscope-therapeutics-appoints-gene-therapy-operations-leader-troy-short-as-senior-vice-president-manufacturing-and-supply-chain\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_TroyShortPR_REV2.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2026\/10\/14\/nanoscope-therapeutics-appoints-gene-therapy-operations-leader-troy-short-as-senior-vice-president-manufacturing-and-supply-chain\/","url":"https:\/\/nanostherapeutics.com\/2026\/10\/14\/nanoscope-therapeutics-appoints-gene-therapy-operations-leader-troy-short-as-senior-vice-president-manufacturing-and-supply-chain\/","name":"Nanoscope Therapeutics Appoints Gene Therapy Operations Leader Troy Short as Senior Vice President, Manufacturing and Supply Chain - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/10\/14\/nanoscope-therapeutics-appoints-gene-therapy-operations-leader-troy-short-as-senior-vice-president-manufacturing-and-supply-chain\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/10\/14\/nanoscope-therapeutics-appoints-gene-therapy-operations-leader-troy-short-as-senior-vice-president-manufacturing-and-supply-chain\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_TroyShortPR_REV2.jpg","datePublished":"2026-10-14T11:40:30+00:00","dateModified":"2026-10-14T14:06:45+00:00","description":"\u5f53\u793e\u306e\u591a\u6a5f\u80fd\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u4f34\u3046\u7db2\u819c\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u80fd\u529b\u3092\u5b9f\u8a3c\u3057\u305f\u521d\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002Nanoscope\u793e\u306f\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u3001\u5e83\u7bc4\u56f2\u306e\u30b9\u30da\u30af\u30c8\u30eb\u3001\u9ad8\u901f\u5fdc\u7b54\u6027\u3001\u8d85\u9ad8\u611f\u5ea6\u3092\u5099\u3048\u305f\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u6700\u521d\u3067\u552f\u4e00\u306e\u5149\u907a\u4f1d\u5b66\u6280\u8853\u3067\u3042\u308bMCO-010\u3092\u958b\u767a\u3057\u307e\u3057\u305f\u3002.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2026\/10\/14\/nanoscope-therapeutics-appoints-gene-therapy-operations-leader-troy-short-as-senior-vice-president-manufacturing-and-supply-chain\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2026\/10\/14\/nanoscope-therapeutics-appoints-gene-therapy-operations-leader-troy-short-as-senior-vice-president-manufacturing-and-supply-chain\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nanostherapeutics.com\/2026\/10\/14\/nanoscope-therapeutics-appoints-gene-therapy-operations-leader-troy-short-as-senior-vice-president-manufacturing-and-supply-chain\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_TroyShortPR_REV2.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_TroyShortPR_REV2.jpg","width":1200,"height":1200},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2026\/10\/14\/nanoscope-therapeutics-appoints-gene-therapy-operations-leader-troy-short-as-senior-vice-president-manufacturing-and-supply-chain\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Appoints Gene Therapy Operations Leader Troy Short as Senior Vice President, Manufacturing and Supply Chain"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","description":"\u5e0c\u671b\u306e\u5149\u3092\u53d6\u308a\u623b\u3059","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d","name":"\u30a6\u30a3\u30eb\u30bd\u30f3 PJ"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/10389","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/comments?post=10389"}],"version-history":[{"count":8,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/10389\/revisions"}],"predecessor-version":[{"id":10411,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/10389\/revisions\/10411"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/media\/10390"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/media?parent=10389"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/categories?post=10389"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/tags?post=10389"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}